MMJ BioPharma’s noble pursuit of scientific advancement has been met with a series of inexplicable roadblocks and bureaucratic hurdles erected by the DEA. In 2018, the company dutifully applied for the necessary licenses to cultivate marijuana for research and development purposes, eagerly anticipating the opportunity to commence clinical trials that could yield life-changing treatments. Yet, despite meticulously following the DEA’s convoluted application process, MMJ BioPharma found itself trapped in a seemingly endless cycle of delays, obfuscation, and stonewalling.
The Tri-State brand built its reputation one pre-roll at a time. Now, after multiple Cannabis…
The Mobb Deep co-founder and Queensbridge native opens The Bridge in Astoria this weekend, with…
Update, June 3, 2026: Jabari Brown was released on June 1 after Paraguay’s Public Prosecutor’s…
The years-long push to lock foreign visitors out of the city’s coffeeshops just died in…
When most people think about major hip-hop festivals, Montana rarely enters the conversation. For decades,…
From a black currant sour to an espresso martini riff, here are five THC cocktails…